74 related articles for article (PubMed ID: 8591734)
1. Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond.
Boado RJ; Kang YS; Wu D; Pardridge WM
Drug Metab Dispos; 1995 Nov; 23(11):1297-300. PubMed ID: 8591734
[No Abstract] [Full Text] [Related]
2. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands H; Gorey-Feret LJ; Cocuzza AJ; Hobbs FW; Chidester D; Trainor GL
Mol Pharmacol; 1994 May; 45(5):932-43. PubMed ID: 8190109
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.
Agrawal S; Tan W; Cai Q; Xie X; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):245-9. PubMed ID: 9212919
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.
Kang YS; Boado RJ; Pardridge WM
Drug Metab Dispos; 1995 Jan; 23(1):55-9. PubMed ID: 7720525
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
[TBL] [Abstract][Full Text] [Related]
9. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
[TBL] [Abstract][Full Text] [Related]
11. Rapid measurement of modified oligonucleotide levels in plasma samples with a fluorophore specific for single-stranded DNA.
Gray GD; Wickstrom E
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):133-40. PubMed ID: 9212903
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal S; Temsamani J; Tang JY
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7595-9. PubMed ID: 1881900
[TBL] [Abstract][Full Text] [Related]
13. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.
Whitesell L; Geselowitz D; Chavany C; Fahmy B; Walbridge S; Alger JR; Neckers LM
Proc Natl Acad Sci U S A; 1993 May; 90(10):4665-9. PubMed ID: 8506315
[TBL] [Abstract][Full Text] [Related]
14. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
[TBL] [Abstract][Full Text] [Related]
15. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
[TBL] [Abstract][Full Text] [Related]
16. Detection and quantitation of PS20, a phosphorothioate oligodeoxynucleotides in monkey plasma.
Shan MM; Song HF; Liu XW; Tang ZM
Acta Pharmacol Sin; 2004 Jun; 25(6):801-6. PubMed ID: 15169635
[TBL] [Abstract][Full Text] [Related]
17. bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver.
Bijsterbosch MK; Manoharan M; Dorland R; Van Veghel R; Biessen EA; Van Berkel TJ
J Pharmacol Exp Ther; 2002 Aug; 302(2):619-26. PubMed ID: 12130724
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oligodeoxynucleotides encapsulated in liposomes: effect of lipid composition and preparation method.
Aliño SF; Crespo J; Tarrasón G; Blaya C; Adán J; Escrig E; Benet M; Crespo A; Peris JE; Piulats J
Xenobiotica; 1999 Dec; 29(12):1283-91. PubMed ID: 10647913
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
Iversen PL; Mata J; Tracewell WG; Zon G
Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
[TBL] [Abstract][Full Text] [Related]
20. Sequence confirmation of synthetic phosphorothioate oligodeoxynucleotides using Sanger sequencing reactions in combination with mass spectrometry.
Lu DD; Chen SH; Zhang W; Liang QD; Wang SQ
Anal Biochem; 2005 Oct; 345(1):81-9. PubMed ID: 16102718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
